Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Research Council grant · Running

MechanoCAR Mechanical sensing and reprogramming of CAR-engineered lymphocytes for next-generation ACT cancer immunotherapy

Coordinator
Ecole Polytechnique Federale De Lausanne, Switzerland
Runs
1 June 2026 to 31 May 2031
Status
Running
EU funding
€2.2m
Total cost
€2.2m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101231572

What the project is doing

In the project's own words, from its summary on CORDIS.

Adoptive cell transfer (ACT) with cytotoxic lymphocytes, including chimeric antigen receptor (CAR)-T cells, is a powerful immunotherapy already demonstrating remarkable success against certain blood cancers. However, its efficacy in treating solid tumors remains limited, with durable responses being rare. Current strategies to improve ACT therapy focus predominantly on biochemical interactions between immune cells and cancer cells.

Yet, emerging evidence highlights the significant influence of biomechanical cues in shaping immune responses and therapeutic outcomes. For instance, the mechanical properties of cancer cells, such as cellular softness, can confer resistance to immune cell-mediated killing, while rigidifying cancer cells can sensitize them toward immune attack leading to enhanced immunotherapy. MechanoCAR explores a novel, under-explored approach: mechanical reprogramming of cytotoxic lymphocytes, including CAR-T and CAR natural killer (NK) cells.

We hypothesize that enhancing the mechano-sensitivity of the lymphocytes could overcome some of the key limitations of ACT therapies, particularly against resistant tumors. First, we aim to uncover and characterize the mechano-sensing and mechano-transduction mechanisms of CARs. Next, we will develop and test innovative mechanical reprogramming strategies to enhance the cytotoxic potential of CAR-T/NK cells in advanced tumor models and further explore the therapeutic potential using patient-derived organoids.

This ambitious and high-reward research has the potential to transform ACT cancer immunotherapy. It addresses significant gaps in current biochemical-centric approaches by introducing a new paradigm focusing on mechanical modulation. If successful, it will provide groundbreaking insights into mechano-immunology, offer a blueprint for designing the next-generation ACT immunotherapies, and ultimately improve treatment outcomes for patients with challenging cancers.

Topics

Who is involved

OrganisationCityCountryRole
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI